Non-α-IL-2

Non-α-IL-2 refers to a class of engineered interleukin-2 (IL-2) variants designed to enhance anti-tumor immunity while mitigating the toxicities associated with wild-type IL-2. These variants are characterized by specific mutations, typically four-point mutations, that prevent their interaction with the alpha chain (CD25) of the IL-2 receptor. By avoiding CD25, which is highly expressed on regulatory T cells (T-regs), Non-α-IL-2 muteins aim to reduce the activation and expansion of immunosuppressive T-regs. Instead, they preferentially stimulate immune effector cells such as CD8+ T cells and natural killer (NK) cells by binding to the intermediate-affinity IL-2 receptor, composed of the beta (CD122) and gamma (CD132) subunits. This selective targeting is intended to improve the therapeutic index of IL-2-based therapies, leading to greater anti-tumor efficacy and reduced side effects like vascular leak syndrome. Several pharmaceutical companies and research institutions are developing Non-α-IL-2 variants for various cancer indications.

Other names

no-alpha IL-2 muteinIL-2 muteinIL2 muteinIL 2 muteinno-alpha interleukin-2 mutein